The US Food and Drug Administration has approved Brilinta (ticagrelor), an oral antiplatelet medicine, to reduce the rate of cardiovascular death and heart attack in adult patients with acute coronary syndrome. The developer is AstraZeneca Plc. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy
